MARKERS FOR ISOCITRATE DEHYDROGENASE INHIBITORS

摘要

The invention provides methods of detecting cancer and detecting activity of IDH inhibitors, and methods of screening for IDH inhibitors by detecting levels of H3K9me2.

主权项

1. A method of detecting cancer in a patient, the method comprising:
a) obtaining a cancer sample from a patient; b) sequencing for the presence of a isocitrate dehydrogenase (IDH) mutation in the cancer sample; c) comparing the IDH mutation sequence to an IDH sequence in a non-cancerous or normal patient sample; and d) assaying for the level of di-methylation (me2) of histone H3 at lysine 9 (H3K9me2) in the cancer sample with an IDH mutation and comparing it with the level of H3K9me2 of a non-cancerous or normal patient sample, and a higher level of H3K9me2 in the cancer sample compared to the non-cancerous or normal patient sample is indicative of cancer.